Graph Therapeutics vs IMU Biosciences
Graph Therapeutics vs IMU Biosciences, compared side by side on 15 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Graph Therapeutics is on 44/100 and IMU Biosciences on 47/100.
Where each one leads
Graph Therapeutics
- domain rating: 27/100 against 23/100
IMU Biosciences
- our overall score: 47/100 against 44/100
- funding raised: $53.0M against $5.0M
At a glance
| Measure | Graph Therapeutics | IMU Biosciences |
|---|---|---|
| What it is | Developing precision medicines for inflammatory and immune-mediated diseases using AI and patient sample analysis. | Decoding the immune system to pioneer a paradigm shift in disease diagnosis and treatment. |
| Category | Biotechnology, Artificial Intelligence, Healthcare, Drug Discovery | Biotechnology, Artificial Intelligence, HealthTech, Drug Discovery |
| Sells toBusiness model | B2B | B2B |
| Offering | Platform | Platform |
| Founded | 2021 | Not published |
| Headquarters | Boston, Austria | London, United Kingdom |
| Status | Active | Active |
Size, funding and growth
| Measure | Graph Therapeutics | IMU Biosciences |
|---|---|---|
| Total funding | $5.0M | $53.0M |
| Latest round | Funding Round | Series A |
| LinkedIn followers | 2,302 | Not published |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Graph Therapeutics | IMU Biosciences |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 44/100 | 47/100 |
| Traction | 33/100 | 39/100 |
| Search visibility | 42/100 | 4/100 |
| Quality | 58/100 | 68/100 |
| Agent readinessHow well an AI agent can read and act on the site | D (41/100) | D (42/100) |
| Domain ratingLink authority, 0-100 | 27/100 | 23/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Graph Therapeutics | IMU Biosciences |
|---|---|---|
| CMS | Framer | Framer |
Graph Therapeutics vs IMU Biosciences: common questions
Which is better, Graph Therapeutics or IMU Biosciences?
On our 0-100 score IMU Biosciences rates higher (47/100 against 44/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 15 data points above: read the rows that match what you are buying for.
How do Graph Therapeutics and IMU Biosciences compare on the numbers?
Graph Therapeutics leads on domain rating (27/100 against 23/100). IMU Biosciences leads on our overall score (47/100 against 44/100), funding raised ($53.0M against $5.0M).
Read the full Graph Therapeutics review and pricing or the IMU Biosciences review and pricing. You can also browse other Graph Therapeutics alternatives we track.